Boston's shares slip further 10% in heavy trading:
This article was originally published in Clinica
Executive Summary
Boston Scientific's fall from grace continues. Last Wednesday saw a further 10% or $2.25 fall in its share price to $21. Analysts could not explain the fall, on a volume three times that of a normal day's trading, but suggested that it may be a reaction to the rumoured slowdown in the hitherto rapid growth of the US stent market.